{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:00:03Z","timestamp":1790006403998,"version":"4.0.1"},"reference-count":329,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"DOI":"10.1038\/s41571-026-01203-5","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:57:49Z","timestamp":1789999069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding and targeting the tumour matrisome"],"prefix":"10.1038","author":[{"given":"Dharma","family":"Pally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9637-6843","authenticated-orcid":false,"given":"Johanna I.","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-5614","authenticated-orcid":false,"given":"Alexandra","family":"Naba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1111\/febs.15776","volume":"288","author":"NK Karamanos","year":"2021","unstructured":"Karamanos, N. K. et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 288, 6850\u20136912 (2021).","journal-title":"FEBS J."},{"key":"1203_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52\u201367 (2010).","journal-title":"Cell"},{"key":"1203_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bjc.1974.62","volume":"29","author":"OT Anastassiades","year":"1974","unstructured":"Anastassiades, O. T. & Pryce, D. M. Fibrosis as in indication of time in infiltrating breast cancer and its importance in prognosis. Br. J. Cancer 29, 232\u2013239 (1974).","journal-title":"Br. J. Cancer"},{"key":"1203_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/jcp.42.2.162","volume":"42","author":"TB Halvorsen","year":"1989","unstructured":"Halvorsen, T. B. & Seim, E. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J. Clin. Pathol. 42, 162\u2013166 (1989).","journal-title":"J. Clin. Pathol."},{"key":"1203_CR6","first-page":"276","volume":"108","author":"SH Barsky","year":"1982","unstructured":"Barsky, S. H., Rao, C. N., Grotendorst, G. R. & Liotta, L. A. Increased content of type V collagen in desmoplasia of human breast carcinoma. Am. J. Pathol. 108, 276\u2013283 (1982).","journal-title":"Am. J. Pathol."},{"key":"1203_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00000478-198008000-00005","volume":"4","author":"Y Shimosato","year":"1980","unstructured":"Shimosato, Y. et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am. J. Surg. Pathol. 4, 365\u2013373 (1980).","journal-title":"Am. J. Surg. Pathol."},{"key":"1203_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-17-0646","volume":"17","author":"A Winer","year":"2018","unstructured":"Winer, A., Adams, S. & Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol. Cancer Ther. 17, 1147\u20131155 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1203_CR9","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1200\/JCO.2004.08.054","volume":"22","author":"JA Sparano","year":"2004","unstructured":"Sparano, J. A. et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 22, 4683\u20134690 (2004).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/jnci\/93.3.178","volume":"93","author":"M Hidalgo","year":"2001","unstructured":"Hidalgo, M. & Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst. 93, 178\u2013193 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"1203_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1470-2045(14)70403-6","volume":"15","author":"OL Chinot","year":"2014","unstructured":"Chinot, O. L. Cilengitide in glioblastoma: when did it fail? Lancet Oncol. 15, 1044\u20131045 (2014).","journal-title":"Lancet Oncol."},{"key":"1203_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/1947601912450586","volume":"2","author":"DA Reardon","year":"2011","unstructured":"Reardon, D. A. & Cheresh, D. Cilengitide. Genes Cancer 2, 1159\u20131165 (2011).","journal-title":"Genes Cancer"},{"key":"1203_CR13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/cancers9090110","volume":"9","author":"S Raab-Westphal","year":"2017","unstructured":"Raab-Westphal, S., Marshall, J. F. & Goodman, S. L. Integrins as therapeutic targets: successes and cancers. Cancers 9, 110 (2017).","journal-title":"Cancers"},{"key":"1203_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/bjc.2016.312","volume":"115","author":"H Hamidi","year":"2016","unstructured":"Hamidi, H., Pietil\u00e4, M. & Ivaska, J. The complexity of integrins in cancer and new scopes for therapeutic targeting. Br. J. Cancer 115, 1017\u20131023 (2016).","journal-title":"Br. J. Cancer"},{"key":"1203_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1158\/0008-5472.CAN-16-1336","volume":"77","author":"YA DeClerck","year":"2017","unstructured":"DeClerck, Y. A., Pienta, K. J., Woodhouse, E. C., Singer, D. S. & Mohla, S. The tumor microenvironment at a turning point knowledge gained over the last decade, and challenges and opportunities ahead: a white paper from the NCI TME Network. Cancer Res. 77, 1051\u20131059 (2017).","journal-title":"Cancer Res."},{"key":"1203_CR16","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M111.014647","volume":"11","author":"A Naba","year":"2012","unstructured":"Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteom. 11, M111.014647 (2012).","journal-title":"Mol. Cell Proteom."},{"key":"1203_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semcdb.2018.06.005","volume":"89","author":"AM Socovich","year":"2019","unstructured":"Socovich, A. M. & Naba, A. The cancer matrisome: from comprehensive characterization to biomarker discovery. Semin. Cell Development. Biol. 89, 157\u2013166 (2019).","journal-title":"Semin. Cell Development. Biol."},{"key":"1203_CR18","doi-asserted-by":"publisher","first-page":"100528","DOI":"10.1016\/j.mcpro.2023.100528","volume":"22","author":"A Naba","year":"2023","unstructured":"Naba, A. Ten years of extracellular matrix proteomics: accomplishments, challenges, and future perspectives. Mol. Cell. Proteom. 22, 100528 (2023).","journal-title":"Mol. Cell. Proteom."},{"key":"1203_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.matbio.2025.08.004","volume":"141","author":"A Page-McCaw","year":"2025","unstructured":"Page-McCaw, A. & Ferrell, N. Basement membrane structure and function: relating biology to mechanics. Matrix Biol. 141, 16\u201331 (2025).","journal-title":"Matrix Biol."},{"key":"1203_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.ctdb.2018.02.005","volume":"130","author":"R Sekiguchi","year":"2018","unstructured":"Sekiguchi, R. & Yamada, K. M. Basement membranes in development and disease. Curr. Top. Dev. Biol. 130, 143\u2013191 (2018).","journal-title":"Curr. Top. Dev. Biol."},{"key":"1203_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"1203_CR22","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup, M. W., Mouw, J. K. & Weaver, V. M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15, 1243\u20131253 (2014).","journal-title":"EMBO Rep."},{"key":"1203_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217\u2013238 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3840","volume":"16","author":"JJF Sleeboom","year":"2024","unstructured":"Sleeboom, J. J. F. et al. The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets. Sci. Transl. Med. 16, eadg3840 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1203_CR25","doi-asserted-by":"publisher","first-page":"D1519","DOI":"10.1093\/nar\/gkac1009","volume":"51","author":"X Shao","year":"2023","unstructured":"Shao, X. et al. MatrisomeDB 2.0: 2023 updates to the ECM-protein knowledge database. Nucleic Acids Res. 51, D1519\u2013D1530 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1203_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41556-018-0145-9","volume":"20","author":"T Celi\u00e0-Terrassa","year":"2018","unstructured":"Celi\u00e0-Terrassa, T. & Kang, Y. Metastatic niche functions and therapeutic opportunities. Nat. Cell Biol. 20, 868\u2013877 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1203_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-19-2961","volume":"80","author":"JD Hebert","year":"2020","unstructured":"Hebert, J. D. et al. Proteomic profiling of the ECM of xenograft breast cancer metastases in different organs reveals distinct metastatic niches. Cancer Res. 80, 1475\u20131485 (2020).","journal-title":"Cancer Res."},{"key":"1203_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41568-025-00798-8","volume":"25","author":"Z Xiao","year":"2025","unstructured":"Xiao, Z. & Pur\u00e9, E. The fibroinflammatory response in cancer. Nat. Rev. Cancer 25, 399\u2013425 https:\/\/doi.org\/10.1038\/s41568-025-00798-8 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1203_CR30","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41580-024-00767-3","volume":"25","author":"A Naba","year":"2024","unstructured":"Naba, A. Mechanisms of assembly and remodelling of the extracellular matrix. Nat. Rev. Mol. Cell Biol. 25, 865\u2013885 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1203_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cells8090984","volume":"8","author":"GB Fields","year":"2019","unstructured":"Fields, G. B. The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma. Cells 8, 984 (2019).","journal-title":"Cells"},{"key":"1203_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.trecan.2025.05.003","volume":"11","author":"JL Chitty","year":"2025","unstructured":"Chitty, J. L. & Cox, T. R. The extracellular matrix in cancer: from understanding to targeting. Trends Cancer 11, 839\u2013849 (2025).","journal-title":"Trends Cancer"},{"key":"1203_CR33","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano, L., Jord\u0101o, M. J. C. & Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 11, 933\u2013959 (2021).","journal-title":"Cancer Discov."},{"key":"1203_CR34","doi-asserted-by":"publisher","first-page":"a004903","DOI":"10.1101\/cshperspect.a004903","volume":"4","author":"RO Hynes","year":"2012","unstructured":"Hynes, R. O. & Naba, A. Overview of the matrisome \u2014 an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 4, a004903 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1203_CR35","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1126\/science.1176009","volume":"326","author":"RO Hynes","year":"2009","unstructured":"Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science 326, 1216\u20131219 (2009).","journal-title":"Science"},{"key":"1203_CR36","doi-asserted-by":"publisher","unstructured":"Naba, A. & Ricard-Blum, S. in Extracellular Matrix Omics (ed. Ricard-Blum, S.) 1\u201316 https:\/\/doi.org\/10.1007\/978-3-030-58330-9_1 (Springer International, 2020).","DOI":"10.1007\/978-3-030-58330-9_1"},{"key":"1203_CR37","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/ar.24086","volume":"303","author":"SR Lamand\u00e9","year":"2020","unstructured":"Lamand\u00e9, S. R. & Bateman, J. F. Genetic disorders of the extracellular matrix. Anat. Rec. 303, 1527\u20131542 (2020).","journal-title":"Anat. Rec."},{"key":"1203_CR38","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3390\/cancers12082046","volume":"12","author":"V Izzi","year":"2020","unstructured":"Izzi, V., Davis, M. N. & Naba, A. Pan-cancer analysis of the genomic alterations and mutations of the matrisome. Cancers 12, 2046 (2020).","journal-title":"Cancers"},{"key":"1203_CR39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1158\/1541-7786.MCR-20-0949","volume":"19","author":"A Trinh","year":"2021","unstructured":"Trinh, A. et al. Genomic alterations during the in situ to invasive ductal breast carcinoma transition shaped by the immune system. Mol. Cancer Res. 19, 623\u2013635 (2021).","journal-title":"Mol. Cancer Res."},{"key":"1203_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189178","volume":"1879","author":"J Hong","year":"2024","unstructured":"Hong, J. et al. Matrisomics: beyond the extracellular matrix for unveiling tumor microenvironment. Biochim. Biophys. Acta Rev. Cancer 1879, 189178 (2024).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1203_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107628","volume":"31","author":"S Davidson","year":"2020","unstructured":"Davidson, S. et al. Single-cell RNA sequencing reveals a dynamic stromal niche that supports tumor growth. Cell Rep. 31, 107628 (2020).","journal-title":"Cell Rep."},{"key":"1203_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-018-0024-3","volume":"556","author":"SF Roerink","year":"2018","unstructured":"Roerink, S. F. et al. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature 556, 457\u2013462 (2018).","journal-title":"Nature"},{"key":"1203_CR43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into lrrc15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"1203_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41698-019-0087-0","volume":"3","author":"SB Lim","year":"2019","unstructured":"Lim, S. B. et al. Pan-cancer analysis connects tumor matrisome to immune response. NPJ Precis. Onc. 3, 15 (2019).","journal-title":"NPJ Precis. Onc."},{"key":"1203_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s42003-025-09270-7","volume":"9","author":"A De","year":"2025","unstructured":"De, A. et al. Single cell spatial profiling of the matrisome identifies region-specific adhesion and signaling networks in glioblastoma. Commun. Biol. 9, 17 (2025).","journal-title":"Commun. Biol."},{"key":"1203_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2025.101261","volume":"16","author":"TM Pentimalli","year":"2025","unstructured":"Pentimalli, T. M. et al. Combining spatial transcriptomics and ECM imaging in 3D for mapping cellular interactions in the tumor microenvironment. Cell Syst. 16, 101261 (2025).","journal-title":"Cell Syst."},{"key":"1203_CR47","doi-asserted-by":"publisher","first-page":"v451","DOI":"10.1093\/neuonc\/noaf201.1788","volume":"27","author":"J McCarty","year":"2025","unstructured":"McCarty, J., De, A., Forero, S., Pirani, A. & Morales, J. TMIC-33. Single cell spatial profiling of matrisome gene expression in glioblastoma. Neuro-Oncology 27, v451 (2025).","journal-title":"Neuro-Oncology"},{"key":"1203_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07582-3","volume":"9","author":"M Bartoschek","year":"2018","unstructured":"Bartoschek, M. et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat. Commun. 9, 5150 (2018).","journal-title":"Nat. Commun."},{"key":"1203_CR49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s43018-026-01146-x","volume":"7","author":"S Pramod","year":"2026","unstructured":"Pramod, S., Lavon, H., Scherz-Shouval, R. & Sherman, M. H. Heterogeneity and plasticity of cancer-associated fibroblasts. Nat. Cancer 7, 583\u2013596 (2026).","journal-title":"Nat. Cancer"},{"key":"1203_CR50","doi-asserted-by":"publisher","first-page":"jcs263927","DOI":"10.1242\/jcs.263927","volume":"138","author":"R Lamba","year":"2025","unstructured":"Lamba, R., Paguntalan, A. M., Petrov, P. B., Naba, A. & Izzi, V. MatriCom, a single-cell RNA-sequencing data mining tool to infer cell-extracellular matrix interactions. J. Cell Sci. 138, jcs263927 (2025).","journal-title":"J. Cell Sci."},{"key":"1203_CR51","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cell.2021.02.055","volume":"184","author":"H Rodriguez","year":"2021","unstructured":"Rodriguez, H., Zenklusen, J. C., Staudt, L. M., Doroshow, J. H. & Lowy, D. R. The next horizon in precision oncology: proteogenomics to inform cancer diagnosis and treatment. Cell 184, 1661\u20131670 (2021).","journal-title":"Cell"},{"key":"1203_CR52","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","volume":"41","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Proteogenomic data and resources for pan-cancer analysis. Cancer Cell 41, 1397\u20131406 (2023).","journal-title":"Cancer Cell"},{"key":"1203_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227\u2013232 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"1203_CR54","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/14789450.2024.2427136","volume":"21","author":"AK Bains","year":"2024","unstructured":"Bains, A. K. & Naba, A. Proteomic insights into the extracellular matrix: a focus on proteoforms and their implications in health and disease. Expert Rev. Proteomics 21, 463\u2013481 https:\/\/doi.org\/10.1080\/14789450.2024.2427136 (2024).","journal-title":"Expert Rev. Proteomics"},{"key":"1203_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2022.100254","volume":"21","author":"KE Burnum-Johnson","year":"2022","unstructured":"Burnum-Johnson, K. E. et al. New views of old proteins: clarifying the enigmatic proteome. Mol. Cell Proteom. 21, 100254 (2022).","journal-title":"Mol. Cell Proteom."},{"key":"1203_CR56","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01308","volume":"3","author":"A Naba","year":"2014","unstructured":"Naba, A., Clauser, K. R., Lamar, J. M., Carr, S. A. & Hynes, R. O. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 3, e01308 (2014).","journal-title":"eLife"},{"key":"1203_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22490-9","volume":"12","author":"C Tian","year":"2021","unstructured":"Tian, C. et al. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nat. Commun. 12, 2328 (2021).","journal-title":"Nat. Commun."},{"key":"1203_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/febs.70344","volume":"293","author":"L Leverton","year":"2026","unstructured":"Leverton, L., Bains, A. K., Isa, I., Ricard-Blum, S. & Naba, A. A guide to building the matrisome interactome: from computational predictions to experimental validation. FEBS J. 293, 42\u201370 (2026).","journal-title":"FEBS J."},{"key":"1203_CR59","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1021\/acs.jproteome.4c00099","volume":"23","author":"JK Macdonald","year":"2024","unstructured":"Macdonald, J. K. et al. The spatial extracellular proteomic tumor microenvironment distinguishes molecular subtypes of hepatocellular carcinoma. J. Proteome Res. 23, 3791\u20133805 (2024).","journal-title":"J. Proteome Res."},{"key":"1203_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl1197","volume":"10","author":"BA Pereira","year":"2024","unstructured":"Pereira, B. A. et al. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Sci. Adv. 10, eadl1197 (2024).","journal-title":"Sci. Adv."},{"key":"1203_CR61","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41590-023-01678-9","volume":"24","author":"LA Walsh","year":"2023","unstructured":"Walsh, L. A. & Quail, D. F. Decoding the tumor microenvironment with spatial technologies. Nat. Immunol. 24, 1982\u20131993 (2023).","journal-title":"Nat. Immunol."},{"key":"1203_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2022.10.003","volume":"114","author":"AM Haack","year":"2022","unstructured":"Haack, A. M., Overall, C. M. & Auf dem Keller, U. Degradomics technologies in matrisome exploration. Matrix Biol. 114, 1\u201317 (2022).","journal-title":"Matrix Biol."},{"key":"1203_CR63","doi-asserted-by":"publisher","first-page":"100688","DOI":"10.1016\/j.mcpro.2023.100688","volume":"23","author":"MA Gillette","year":"2024","unstructured":"Gillette, M. A., Jimenez, C. R. & Carr, S. A. Clinical proteomics: a promise becoming reality. Mol. Cell. Proteom. 23, 100688 (2024).","journal-title":"Mol. Cell. Proteom."},{"key":"1203_CR64","doi-asserted-by":"publisher","first-page":"a004994","DOI":"10.1101\/cshperspect.a004994","volume":"3","author":"ID Campbell","year":"2011","unstructured":"Campbell, I. D. & Humphries, M. J. Integrin structure, activation, and interactions. Cold Spring Harb. Perspect. Biol. 3, a004994 (2011).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1203_CR65","first-page":"363","volume":"12","author":"E Henriet","year":"2018","unstructured":"Henriet, E. et al. Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer. Cell Adhes. Migr. 12, 363\u2013377 (2018).","journal-title":"Cell Adhes. Migr."},{"key":"1203_CR66","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1111\/febs.16258","volume":"289","author":"I Liebscher","year":"2022","unstructured":"Liebscher, I. et al. A guide to adhesion GPCR research. FEBS J. 289, 7610\u20137630 (2022).","journal-title":"FEBS J."},{"key":"1203_CR67","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1369\/0022155420930112","volume":"68","author":"B Jang","year":"2020","unstructured":"Jang, B. et al. Emerging role of syndecans in extracellular matrix remodeling in cancer. J. Histochem. Cytochem. 68, 863\u2013870 (2020).","journal-title":"J. Histochem. Cytochem."},{"key":"1203_CR68","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/s41592-024-02564-4","volume":"22","author":"HT Nia","year":"2025","unstructured":"Nia, H. T., Munn, L. L. & Jain, R. K. Probing the physical hallmarks of cancer. Nat. Methods 22, 1800\u20131818 (2025).","journal-title":"Nat. Methods"},{"key":"1203_CR69","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41568-024-00704-8","volume":"24","author":"JC Ashworth","year":"2024","unstructured":"Ashworth, J. C. & Cox, T. R. The importance of 3D fibre architecture in cancer and implications for biomaterial model design. Nat. Rev. Cancer 24, 461\u2013479 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.copbio.2016.02.007","volume":"40","author":"F Spill","year":"2016","unstructured":"Spill, F., Reynolds, D. S., Kamm, R. D. & Zaman, M. H. Impact of the physical microenvironment on tumor progression and metastasis. Curr. Opin. Biotechnol. 40, 41\u201348 (2016).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1203_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ceb.2021.05.004","volume":"72","author":"A Ray","year":"2021","unstructured":"Ray, A. & Provenzano, P. P. Aligned forces: origins and mechanisms of cancer dissemination guided by ECM architecture. Curr. Opin. Cell Biol. 72, 63\u201371 (2021).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1203_CR72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41580-019-0134-2","volume":"20","author":"JZ Kechagia","year":"2019","unstructured":"Kechagia, J. Z., Ivaska, J. & Roca-Cusachs, P. Integrins as biomechanical sensors of the microenvironment. Nat. Rev. Mol. Cell Biol. 20, 457\u2013473 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1203_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade2120","volume":"9","author":"F Baschieri","year":"2023","unstructured":"Baschieri, F. et al. Fibroblasts generate topographical cues that steer cancer cell migration. Sci. Adv. 9, eade2120 (2023).","journal-title":"Sci. Adv."},{"key":"1203_CR74","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"1203_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal. Transduct. Target. Ther. 6, 153 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1203_CR76","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.3390\/cancers12102916","volume":"12","author":"VE Krisnawan","year":"2020","unstructured":"Krisnawan, V. E., Stanley, J. A., Schwarz, J. K. & DeNardo, D. G. Tumor microenvironment as a regulator of radiation therapy: new insights into stromal-mediated radioresistance. Cancers 12, 2916 (2020).","journal-title":"Cancers"},{"key":"1203_CR77","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek, D. E. et al. Collagen density regulates the activity of tumor-infiltrating T cells. J. Immunother. Cancer 7, 68 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1203_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.matbio.2023.04.002","volume":"119","author":"A Naik","year":"2023","unstructured":"Naik, A. & Leask, A. Tumor-associated fibrosis impairs the response to immunotherapy. Matrix Biol. 119, 125\u2013140 (2023).","journal-title":"Matrix Biol."},{"key":"1203_CR79","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.4049\/jimmunol.1900789","volume":"205","author":"AMH Larsen","year":"2020","unstructured":"Larsen, A. M. H. et al. Collagen density modulates the immunosuppressive functions of macrophages. J. Immunol. 205, 1461\u20131472 (2020).","journal-title":"J. Immunol."},{"key":"1203_CR80","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41568-024-00740-4","volume":"24","author":"L Arpinati","year":"2024","unstructured":"Arpinati, L., Carradori, G. & Scherz-Shouval, R. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat. Rev. Cancer 24, 676\u2013693 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR81","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1158\/2767-9764.CRC-25-0460","volume":"6","author":"JM Considine","year":"2026","unstructured":"Considine, J. M. et al. Identification of pancreatic ductal adenocarcinoma extracellular matrix signatures from in-depth proteomic profiling that correlate with lymphocyte infiltration. Cancer Res. Commun. 6, 1319\u20131335 https:\/\/doi.org\/10.1158\/2767-9764.CRC-25-0460 (2026).","journal-title":"Cancer Res. Commun."},{"key":"1203_CR82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.matbio.2023.07.003","volume":"121","author":"L Closset","year":"2023","unstructured":"Closset, L. et al. The extracellular matrix \u2014 immune microenvironment crosstalk in cancer therapy: challenges and opportunities. Matrix Biol. 121, 217\u2013228 (2023).","journal-title":"Matrix Biol."},{"key":"1203_CR83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.matbio.2018.01.024","volume":"75\u201376","author":"M Vizovi\u0161ek","year":"2019","unstructured":"Vizovi\u0161ek, M., Fonovi\u0107, M. & Turk, B. Cysteine cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond. Matrix Biol. 75\u201376, 141\u2013159 (2019).","journal-title":"Matrix Biol."},{"key":"1203_CR84","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1203_CR85","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220011","volume":"219","author":"DF Quail","year":"2022","unstructured":"Quail, D. F. et al. Neutrophil phenotypes and functions in cancer: a consensus statement. J. Exp. Med. 219, e20220011 (2022).","journal-title":"J. Exp. Med."},{"key":"1203_CR86","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1083\/jcb.201903066","volume":"218","author":"J Chang","year":"2019","unstructured":"Chang, J. & Chaudhuri, O. Beyond proteases: basement membrane mechanics and cancer invasion. J. Cell Biol. 218, 2456\u20132469 (2019).","journal-title":"J. Cell Biol."},{"key":"1203_CR87","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/exd.12435","volume":"23","author":"S Ricard-Blum","year":"2014","unstructured":"Ricard-Blum, S. & Salza, R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Exp. Dermatol. 23, 457\u2013463 (2014).","journal-title":"Exp. Dermatol."},{"key":"1203_CR88","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.bbagen.2013.12.029","volume":"1840","author":"JC Monboisse","year":"2014","unstructured":"Monboisse, J. C., Oudart, J. B., Ramont, L., Brassart-Pasco, S. & Maquart, F. X. Matrikines from basement membrane collagens: a new anti-cancer strategy. Biochim. Biophys. Acta 1840, 2589\u20132598 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1203_CR89","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fonc.2020.00397","volume":"10","author":"S Brassart-Pasco","year":"2020","unstructured":"Brassart-Pasco, S. et al. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front. Oncol. 10, 397 (2020).","journal-title":"Front. Oncol."},{"key":"1203_CR90","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","volume":"5","author":"KM Tharp","year":"2024","unstructured":"Tharp, K. M. et al. Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat. Cancer 5, 1045\u20131062 (2024).","journal-title":"Nat. Cancer"},{"key":"1203_CR91","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41556-018-0131-2","volume":"20","author":"H Mohammadi","year":"2018","unstructured":"Mohammadi, H. & Sahai, E. Mechanisms and impact of altered tumour mechanics. Nat. Cell Biol. 20, 766\u2013774 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1203_CR92","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41586-020-2612-2","volume":"584","author":"O Chaudhuri","year":"2020","unstructured":"Chaudhuri, O., Cooper-White, J., Janmey, P. A., Mooney, D. J. & Shenoy, V. B. The impact of extracellular matrix viscoelasticity on cellular behavior. Nature 584, 535\u2013546 (2020).","journal-title":"Nature"},{"key":"1203_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41580-023-00583-1","volume":"24","author":"A Saraswathibhatla","year":"2023","unstructured":"Saraswathibhatla, A., Indana, D. & Chaudhuri, O. Cell-extracellular matrix mechanotransduction in 3D. Nat. Rev. Mol. Cell Biol. 24, 495\u2013516 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1203_CR94","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41568-024-00745-z","volume":"24","author":"JA Linke","year":"2024","unstructured":"Linke, J. A., Munn, L. L. & Jain, R. K. Compressive stresses in cancer: characterization and implications for tumour progression and treatment. Nat. Rev. Cancer 24, 768\u2013791 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR95","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1007\/s00330-013-2866-2","volume":"23","author":"JM Chang","year":"2013","unstructured":"Chang, J. M. et al. Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer. Eur. Radiol. 23, 2450\u20132458 (2013).","journal-title":"Eur. Radiol."},{"key":"1203_CR96","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1148\/radiol.14131164","volume":"275","author":"Q Lu","year":"2015","unstructured":"Lu, Q. et al. Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. Radiology 275, 880\u2013888 (2015).","journal-title":"Radiology"},{"key":"1203_CR97","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s44341-025-00014-6","volume":"2","author":"O Courbot","year":"2025","unstructured":"Courbot, O. & Elosegui-Artola, A. The role of extracellular matrix viscoelasticity in development and disease. NPJ Biol. Phys. Mech. 2, 10 (2025).","journal-title":"NPJ Biol. Phys. Mech."},{"key":"1203_CR98","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi, H. & Ivaska, J. Every step of the way: integrins in cancer progression and metastasis. Nat. Rev. Cancer 18, 533\u2013548 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.54","volume":"6","author":"AJ Rice","year":"2017","unstructured":"Rice, A. J. et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 6, e352 (2017).","journal-title":"Oncogenesis"},{"key":"1203_CR100","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/ncponc1089","volume":"5","author":"EA Turley","year":"2008","unstructured":"Turley, E. A., Veiseh, M., Radisky, D. C. & Bissell, M. J. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5, 280\u2013290 (2008).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"1203_CR101","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ncb3157","volume":"17","author":"SC Wei","year":"2015","unstructured":"Wei, S. C. et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat. Cell Biol. 17, 678\u2013688 (2015).","journal-title":"Nat. Cell Biol."},{"key":"1203_CR102","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s43018-020-0088-5","volume":"1","author":"E Risson","year":"2020","unstructured":"Risson, E., Nobre, A. R., Maguer-Satta, V. & Aguirre-Ghiso, J. A. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat. Cancer 1, 672\u2013680 (2020).","journal-title":"Nat. Cancer"},{"key":"1203_CR103","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/1878-0261.12022","volume":"11","author":"A Dasgupta","year":"2017","unstructured":"Dasgupta, A., Lim, A. R. & Ghajar, C. M. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol. Oncol. 11, 40\u201361 (2017).","journal-title":"Mol. Oncol."},{"key":"1203_CR104","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10555-023-10094-2","volume":"42","author":"A Mukherjee","year":"2023","unstructured":"Mukherjee, A. & Bravo-Cordero, J. J. Regulation of dormancy during tumor dissemination: the role of the ECM. Cancer Metastasis Rev. 42, 99\u2013112 (2023).","journal-title":"Cancer Metastasis Rev."},{"key":"1203_CR105","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807\u2013817 (2013).","journal-title":"Nat. Cell Biol."},{"key":"1203_CR106","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s43018-021-00291-9","volume":"3","author":"JS Di Martino","year":"2022","unstructured":"Di Martino, J. S. et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. Nat. Cancer 3, 90\u2013107 (2022).","journal-title":"Nat. Cancer"},{"key":"1203_CR107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s43018-021-00297-3","volume":"3","author":"J Dai","year":"2022","unstructured":"Dai, J. et al. Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nat. Cancer 3, 25\u201342 (2022).","journal-title":"Nat. Cancer"},{"key":"1203_CR108","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s12276-020-0423-z","volume":"52","author":"S-Y Park","year":"2020","unstructured":"Park, S.-Y. & Nam, J.-S. The force awakens: metastatic dormant cancer cells. Exp. Mol. Med. 52, 569\u2013581 (2020).","journal-title":"Exp. Mol. Med."},{"key":"1203_CR109","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-09-2356","volume":"70","author":"D Barkan","year":"2010","unstructured":"Barkan, D. et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70, 5706\u20135716 (2010).","journal-title":"Cancer Res."},{"key":"1203_CR110","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","volume":"15","author":"Z Mai","year":"2024","unstructured":"Mai, Z., Lin, Y., Lin, P., Zhao, X. & Cui, L. Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy. Cell Death Dis. 15, 307 (2024).","journal-title":"Cell Death Dis."},{"key":"1203_CR111","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/s41416-021-01680-8","volume":"126","author":"B Darvishi","year":"2022","unstructured":"Darvishi, B., Eisavand, M. R., Majidzadeh-A, K. & Farahmand, L. Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. Br. J. Cancer 126, 1253\u20131263 (2022).","journal-title":"Br. J. Cancer"},{"key":"1203_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110 (2023).","journal-title":"Nat. Commun."},{"key":"1203_CR113","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.matbio.2024.04.003","volume":"130","author":"SM Haake","year":"2024","unstructured":"Haake, S. M., Rios, B. L., Pozzi, A. & Zent, R. Integrating integrins with the hallmarks of cancer. Matrix Biol. 130, 20\u201335 (2024).","journal-title":"Matrix Biol."},{"key":"1203_CR114","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","volume":"26","author":"MR Chastney","year":"2025","unstructured":"Chastney, M. R., Kaivola, J., Lepp\u00e4nen, V.-M. & Ivaska, J. The role and regulation of integrins in cell migration and invasion. Nat. Rev. Mol. Cell Biol. 26, 147\u2013167 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1203_CR115","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrd.2015.10","volume":"15","author":"K Ley","year":"2016","unstructured":"Ley, K., Rivera-Nieves, J., Sandborn, W. J. & Shattil, S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat. Rev. Drug Discov. 15, 173\u2013183 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1203_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"X Pang","year":"2023","unstructured":"Pang, X. et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal. Transduct. Target. Ther. 8, 1 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1203_CR117","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","volume":"21","author":"RJ Slack","year":"2022","unstructured":"Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G. & Hatley, R. J. D. Emerging therapeutic opportunities for integrin inhibitors. Nat. Rev. Drug Discov. 21, 60\u201378 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1203_CR118","doi-asserted-by":"publisher","first-page":"a005017","DOI":"10.1101\/cshperspect.a005017","volume":"3","author":"JS Munger","year":"2011","unstructured":"Munger, J. S. & Sheppard, D. Cross talk among TGF-\u03b2 signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb. Perspect. Biol. 3, a005017 (2011).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1203_CR119","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50, 924\u2013940 (2019).","journal-title":"Immunity"},{"key":"1203_CR120","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9, J. & Sheppard, D. TGF-\u03b2 signaling in health and disease. Cell 186, 4007\u20134037 (2023).","journal-title":"Cell"},{"key":"1203_CR121","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.matbio.2015.05.006","volume":"47","author":"B Hinz","year":"2015","unstructured":"Hinz, B. The extracellular matrix and transforming growth factor-\u03b21: tale of a strained relationship. Matrix Biol. 47, 54\u201365 (2015).","journal-title":"Matrix Biol."},{"key":"1203_CR122","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1091\/mbc.e09-07-0590","volume":"21","author":"N Ferrara","year":"2010","unstructured":"Ferrara, N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol. Biol. Cell 21, 687\u2013690 (2010).","journal-title":"Mol. Biol. Cell"},{"key":"1203_CR123","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cell.2014.10.008","volume":"159","author":"CK Domigan","year":"2014","unstructured":"Domigan, C. K. & Iruela-Arispe, M. L. Stealing VEGF from thy neighbor. Cell 159, 473\u2013474 (2014).","journal-title":"Cell"},{"key":"1203_CR124","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee, C. et al. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal. Transduct. Target. Ther. 10, 170 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1203_CR125","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-07-6390","volume":"68","author":"CC Park","year":"2008","unstructured":"Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J. & Bissell, M. J. \u03b21 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398\u20134405 (2008).","journal-title":"Cancer Res."},{"key":"1203_CR126","doi-asserted-by":"publisher","first-page":"a026781","DOI":"10.1101\/cshperspect.a026781","volume":"7","author":"E Hirata","year":"2017","unstructured":"Hirata, E. & Sahai, E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb. Perspect. Med. 7, a026781 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1203_CR127","volume":"2012","author":"F Aoudjit","year":"2012","unstructured":"Aoudjit, F. & Vuori, K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 283181 (2012).","journal-title":"Chemother. Res. Pract."},{"key":"1203_CR128","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1158\/0008-5472.CAN-06-4162","volume":"67","author":"SM Pupa","year":"2007","unstructured":"Pupa, S. M. et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 67, 4271\u20134277 (2007).","journal-title":"Cancer Res."},{"key":"1203_CR129","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/neuonc\/noac237","volume":"25","author":"I Korovina","year":"2022","unstructured":"Korovina, I., Vehlow, A., Temme, A. & Cordes, N. Targeting integrin \u03b12 as potential strategy for radiochemosensitization of glioblastoma. Neuro-Oncology 25, 648\u2013661 (2022).","journal-title":"Neuro-Oncology"},{"key":"1203_CR130","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1111\/febs.70069","volume":"292","author":"A Lo Cicero","year":"2025","unstructured":"Lo Cicero, A. et al. Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids. FEBS J. 292, 3494\u20133507 (2025).","journal-title":"FEBS J."},{"key":"1203_CR131","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.matbio.2022.08.002","volume":"112","author":"JR Guarin","year":"2022","unstructured":"Guarin, J. R., Fatherree, J. P. & Oudin, M. J. Chemotherapy treatment induces pro-invasive changes in liver ECM composition. Matrix Biol. 112, 20\u201338 (2022).","journal-title":"Matrix Biol."},{"key":"1203_CR132","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van \u2019t Veer","year":"2002","unstructured":"van \u2019t Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530\u2013536 (2002).","journal-title":"Nature"},{"key":"1203_CR133","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999\u20132009 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1203_CR134","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/gcc.23014","volume":"61","author":"JC Haan","year":"2022","unstructured":"Haan, J. C. et al. MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. Genes Chromosomes Cancer 61, 148\u2013160 (2022).","journal-title":"Genes Chromosomes Cancer"},{"key":"1203_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100756","volume":"13","author":"L Mittempergher","year":"2020","unstructured":"Mittempergher, L. et al. Performance characteristics of the BluePrint\u00ae breast cancer diagnostic test. Transl. Oncol. 13, 100756 (2020).","journal-title":"Transl. Oncol."},{"key":"1203_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01664-x","volume":"25","author":"MC Liefaard","year":"2023","unstructured":"Liefaard, M. C. et al. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer. Breast Cancer Res. 25, 71 (2023).","journal-title":"Breast Cancer Res."},{"key":"1203_CR137","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817\u20132826 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1203_CR138","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR139","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/HEP.0000000000000362","volume":"78","author":"R Desert","year":"2023","unstructured":"Desert, R. et al. Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT\/TGFB signatures, associated with poor outcome. Hepatology 78, 741 (2023).","journal-title":"Hepatology"},{"key":"1203_CR140","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/bjc.2017.458","volume":"118","author":"AE Yuzhalin","year":"2018","unstructured":"Yuzhalin, A. E., Urbonas, T., Silva, M. A., Muschel, R. J. & Gordon-Weeks, A. N. A core matrisome gene signature predicts cancer outcome. Br. J. Cancer 118, 435\u2013440 (2018).","journal-title":"Br. J. Cancer"},{"key":"1203_CR141","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","volume":"8","author":"OMT Pearce","year":"2018","unstructured":"Pearce, O. M. T. et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 8, 304\u2013319 (2018).","journal-title":"Cancer Discov."},{"key":"1203_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24009-8","volume":"12","author":"EA Pietil\u00e4","year":"2021","unstructured":"Pietil\u00e4, E. A. et al. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nat. Commun. 12, 3904 (2021).","journal-title":"Nat. Commun."},{"key":"1203_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00428-8","volume":"8","author":"M Hoogstraat","year":"2022","unstructured":"Hoogstraat, M. et al. Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. NPJ Breast Cancer 8, 60 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"1203_CR144","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nm.1908","volume":"15","author":"P Farmer","year":"2009","unstructured":"Farmer, P. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15, 68\u201374 (2009).","journal-title":"Nat. Med."},{"key":"1203_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01430-6","volume":"8","author":"SB Lim","year":"2017","unstructured":"Lim, S. B., Tan, S. J., Lim, W.-T. & Lim, C. T. An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. Nat. Commun. 8, 1734 (2017).","journal-title":"Nat. Commun."},{"key":"1203_CR146","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/1097-0142(197605)37:5<2486::AID-CNCR2820370542>3.0.CO;2-8","volume":"37","author":"JN Wolfe","year":"1976","unstructured":"Wolfe, J. N. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37, 2486\u20132492 (1976).","journal-title":"Cancer"},{"key":"1203_CR147","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1186\/bcr622","volume":"5","author":"S Alowami","year":"2003","unstructured":"Alowami, S., Troup, S., Al-Haddad, S., Kirkpatrick, I. & Watson, P. H. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 5, R129\u2013R135 (2003).","journal-title":"Breast Cancer Res."},{"key":"1203_CR148","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0664-2","volume":"18","author":"JC McConnell","year":"2016","unstructured":"McConnell, J. C. et al. Increased peri-ductal collagen micro-organization may contribute to raised mammographic density. Breast Cancer Res. 18, 5 (2016).","journal-title":"Breast Cancer Res."},{"key":"1203_CR149","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMoa013390","volume":"347","author":"NF Boyd","year":"2002","unstructured":"Boyd, N. F. et al. Heritability of mammographic density, a risk factor for breast cancer. N. Engl. J. Med. 347, 886\u2013894 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1203_CR150","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1055-9965.EPI-06-0034","volume":"15","author":"VA McCormack","year":"2006","unstructured":"McCormack, V. A. & dos Santos Silva, I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1159\u20131169 (2006).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1203_CR151","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1007\/s00330-022-08617-6","volume":"32","author":"RM Mann","year":"2022","unstructured":"Mann, R. M. et al. Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur. Radiol. 32, 4036\u20134045 (2022).","journal-title":"Eur. Radiol."},{"key":"1203_CR152","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10549-024-07269-y","volume":"205","author":"D Perera","year":"2024","unstructured":"Perera, D. et al. The distribution of breast density in women aged 18 years and older. Breast Cancer Res. Treat. 205, 521\u2013531 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"1203_CR153","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.sult.2017.05.010","volume":"39","author":"RG Barr","year":"2018","unstructured":"Barr, R. G. The role of sonoelastography in breast lesions. Semin. Ultrasound CT MR 39, 98\u2013105 (2018).","journal-title":"Semin. Ultrasound CT MR"},{"key":"1203_CR154","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00330-023-10057-9","volume":"34","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Evaluation of standard breast ultrasonography by adding two-dimensional and three-dimensional shear wave elastography: a prospective, multicenter trial. Eur. Radiol. 34, 945\u2013956 (2024).","journal-title":"Eur. Radiol."},{"key":"1203_CR155","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-17-3262","volume":"24","author":"J Riegler","year":"2018","unstructured":"Riegler, J. et al. Tumor elastography and its association with collagen and the tumor microenvironment. Clin. Cancer Res. 24, 4455\u20134467 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109991","volume":"144","author":"S Hong","year":"2021","unstructured":"Hong, S. et al. Diagnostic performance of elastography for breast non-mass lesions: a systematic review and meta-analysis. Eur. J. Radiol. 144, 109991 (2021).","journal-title":"Eur. J. Radiol."},{"key":"1203_CR157","doi-asserted-by":"publisher","first-page":"300","DOI":"10.14366\/usg.17024","volume":"36","author":"JH Youk","year":"2017","unstructured":"Youk, J. H., Gweon, H. M. & Son, E. J. Shear-wave elastography in breast ultrasonography: the state of the art. Ultrasonography 36, 300\u2013309 (2017).","journal-title":"Ultrasonography"},{"key":"1203_CR158","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/jimaging11070221","volume":"11","author":"YAY Selim","year":"2025","unstructured":"Selim, Y. A. Y., Sabit, H., Arneth, B. & Shaaban, M. A. Diagnostic accuracy of sonoelastography for breast lesions: a meta-analysis comparing strain and shear wave elastography. J. Imaging 11, 221 (2025).","journal-title":"J. Imaging"},{"key":"1203_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/JMU.JMU_108_18","volume":"27","author":"J-H Wang","year":"2019","unstructured":"Wang, J.-H. Application of ultrasound liver elastography to the diagnosis and monitoring of liver disease. J. Med. Ultrasound 27, 1\u20132 (2019).","journal-title":"J. Med. Ultrasound"},{"key":"1203_CR160","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1016\/j.acra.2024.12.061","volume":"32","author":"AF Gomes","year":"2025","unstructured":"Gomes, A. F. et al. Comparing the diagnostic performance of ultrasound elastography and magnetic resonance imaging to differentiate benign and malignant breast lesions: a systematic review and meta-analysis. Acad. Radiol. 32, 4421\u20134434 (2025).","journal-title":"Acad. Radiol."},{"key":"1203_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39085-1","volume":"14","author":"C Stashko","year":"2023","unstructured":"Stashko, C. et al. A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer. Nat. Commun. 14, 3561 (2023).","journal-title":"Nat. Commun."},{"key":"1203_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30156-3","volume":"13","author":"A Weber","year":"2023","unstructured":"Weber, A., Vivanco, M. D. & Toca-Herrera, J. L. Application of self-organizing maps to AFM-based viscoelastic characterization of breast cancer cell mechanics. Sci. Rep. 13, 3087 (2023).","journal-title":"Sci. Rep."},{"key":"1203_CR163","doi-asserted-by":"publisher","first-page":"100970","DOI":"10.1016\/j.mtbio.2024.100970","volume":"25","author":"T Kulkarni","year":"2024","unstructured":"Kulkarni, T., Robinson, O.-M., Dutta, A., Mukhopadhyay, D. & Bhattacharya, S. Machine learning-based approach for automated classification of cell and extracellular matrix using nanomechanical properties. Mater. Today Bio. 25, 100970 (2024).","journal-title":"Mater. Today Bio."},{"key":"1203_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08838-6","volume":"7","author":"M Polasek","year":"2017","unstructured":"Polasek, M. et al. Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Sci. Rep. 7, 8114 (2017).","journal-title":"Sci. Rep."},{"key":"1203_CR165","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1073\/pnas.1423021112","volume":"112","author":"S Xue","year":"2015","unstructured":"Xue, S. et al. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc. Natl Acad. Sci. USA 112, 6607\u20136612 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1203_CR166","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s11095-011-0635-y","volume":"29","author":"M Tan","year":"2012","unstructured":"Tan, M. et al. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model. Pharm. Res. 29, 953\u2013960 (2012).","journal-title":"Pharm. Res."},{"key":"1203_CR167","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1158\/1078-0432.CCR-18-1359","volume":"26","author":"DJ Erstad","year":"2020","unstructured":"Erstad, D. J. et al. Fibrotic response to neoadjuvant therapy predicts survival in pancreatic cancer and is measurable with collagen-targeted molecular MRI. Clin. Cancer Res. 26, 5007\u20135018 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR168","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.7150\/thno.100116","volume":"14","author":"SA Esfahani","year":"2024","unstructured":"Esfahani, S. A. et al. Collagen type I PET\/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Theranostics 14, 5745\u20135761 (2024).","journal-title":"Theranostics"},{"key":"1203_CR169","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/his.13489","volume":"73","author":"GW van Pelt","year":"2018","unstructured":"van Pelt, G. W. et al. The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. Histopathology 73, 197\u2013206 (2018).","journal-title":"Histopathology"},{"key":"1203_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.100933","volume":"7","author":"LA Shaktah","year":"2025","unstructured":"Shaktah, L. A. et al. Application of artificial intelligence and digital tools in cancer pathology. Lancet Digit. Health 7, 100933 (2025).","journal-title":"Lancet Digit. Health"},{"key":"1203_CR171","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/path.6153","volume":"260","author":"X Fu","year":"2023","unstructured":"Fu, X., Sahai, E. & Wilkins, A. Application of digital pathology-based advanced analytics of tumour microenvironment organisation to predict prognosis and therapeutic response. J. Pathol. 260, 578\u2013591 (2023).","journal-title":"J. Pathol."},{"key":"1203_CR172","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/ten.tea.2024.0039","volume":"30","author":"JL Guo","year":"2024","unstructured":"Guo, J. L. et al. Hematoxylin and eosin architecture uncovers clinically divergent niches in pancreatic cancer. Tissue Eng. Part A 30, 605\u2013613 (2024).","journal-title":"Tissue Eng. Part A"},{"key":"1203_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00310-z","volume":"7","author":"H Li","year":"2021","unstructured":"Li, H. et al. Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. NPJ Breast Cancer 7, 104 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"1203_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60824-z","volume":"16","author":"I Garberis","year":"2025","unstructured":"Garberis, I. et al. Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slides. Nat. Commun. 16, 5876 (2025).","journal-title":"Nat. Commun."},{"key":"1203_CR175","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1369\/0022155414545787","volume":"62","author":"R Lattouf","year":"2014","unstructured":"Lattouf, R. et al. Picrosirius red staining: a useful tool to appraise collagen networks in normal and pathological tissues. J. Histochem. Cytochem. 62, 751\u2013758 (2014).","journal-title":"J. Histochem. Cytochem."},{"key":"1203_CR176","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01002772","volume":"11","author":"LCU Junqueira","year":"1979","unstructured":"Junqueira, L. C. U., Bignolas, G. & Brentani, R. R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11, 447\u2013455 (1979).","journal-title":"Histochem. J."},{"key":"1203_CR177","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nprot.2012.009","volume":"7","author":"X Chen","year":"2012","unstructured":"Chen, X., Nadiarynkh, O., Plotnikov, S. & Campagnola, P. J. Second harmonic generation microscopy for quantitative analysis of collagen fibrillar structure. Nat. Protoc. 7, 654\u2013669 (2012).","journal-title":"Nat. Protoc."},{"key":"1203_CR178","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/B978-0-12-420138-5.00028-8","volume":"123","author":"A Keikhosravi","year":"2014","unstructured":"Keikhosravi, A., Bredfeldt, J. S., Sagar, A. K. & Eliceiri, K. W. Second-harmonic generation imaging of cancer. Methods Cell Biol. 123, 531\u2013546 (2014).","journal-title":"Methods Cell Biol."},{"key":"1203_CR179","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ajpath.2010.11.076","volume":"178","author":"MW Conklin","year":"2011","unstructured":"Conklin, M. W. et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 178, 1221\u20131232 (2011).","journal-title":"Am. J. Pathol."},{"key":"1203_CR180","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/exd.14713","volume":"32","author":"M Send\u00edn-Mart\u00edn","year":"2023","unstructured":"Send\u00edn-Mart\u00edn, M. et al. Quantitative collagen analysis using second harmonic generation images for the detection of basal cell carcinoma with ex vivo multiphoton microscopy. Exp. Dermatol. 32, 392\u2013402 (2023).","journal-title":"Exp. Dermatol."},{"key":"1203_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02146-7","volume":"19","author":"G Xi","year":"2021","unstructured":"Xi, G. et al. Computer-assisted quantification of tumor-associated collagen signatures to improve the prognosis prediction of breast cancer. BMC Med. 19, 273 (2021).","journal-title":"BMC Med."},{"key":"1203_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3090-2","volume":"17","author":"KB Tilbury","year":"2017","unstructured":"Tilbury, K. B. et al. Stromal alterations in ovarian cancers via wavelength dependent second harmonic generation microscopy and optical scattering. BMC Cancer 17, 102 (2017).","journal-title":"BMC Cancer"},{"key":"1203_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88984-4","volume":"15","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Multiphoton imaging-based quantifiable collagen signatures for predicting outcomes in patients with pancreatic ductal adenocarcinoma. Sci. Rep. 15, 4414 (2025).","journal-title":"Sci. Rep."},{"key":"1203_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07713-4","volume":"20","author":"DE Desa","year":"2020","unstructured":"Desa, D. E. et al. Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction. BMC Cancer 20, 1217 (2020).","journal-title":"BMC Cancer"},{"key":"1203_CR185","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02017-6","volume":"27","author":"S Heydari","year":"2025","unstructured":"Heydari, S. et al. The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review. Breast Cancer Res. 27, 69 (2025).","journal-title":"Breast Cancer Res."},{"key":"1203_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13623-1","volume":"12","author":"K Mirsanaye","year":"2022","unstructured":"Mirsanaye, K. et al. Machine learning-enabled cancer diagnostics with widefield polarimetric second-harmonic generation microscopy. Sci. Rep. 12, 10290 (2022).","journal-title":"Sci. Rep."},{"key":"1203_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-23780-8","volume":"15","author":"JR Gagnon","year":"2025","unstructured":"Gagnon, J. R. et al. Label-free histological identification of intraductal carcinoma of the prostate using texture analysis-based multimodal stimulated Raman scattering microscopy. Sci. Rep. 15, 39874 (2025).","journal-title":"Sci. Rep."},{"key":"1203_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67857-y","volume":"10","author":"E Gavgiotaki","year":"2020","unstructured":"Gavgiotaki, E. et al. Third harmonic generation microscopy distinguishes malignant cell grade in human breast tissue biopsies. Sci. Rep. 10, 11055 (2020).","journal-title":"Sci. Rep."},{"key":"1203_CR189","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/978-1-4939-7113-8_28","volume":"1627","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Keikhosravi, A., Mehta, G. S., Drifka, C. R. & Eliceiri, K. W. Methods for quantifying fibrillar collagen alignment. Methods Mol. Biol. 1627, 429\u2013451 (2017).","journal-title":"Methods Mol. Biol."},{"key":"1203_CR190","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000880","volume":"4","author":"E Wershof","year":"2021","unstructured":"Wershof, E. et al. A FIJI macro for quantifying pattern in extracellular matrix. Life Sci. Alliance 4, e202000880 (2021).","journal-title":"Life Sci. Alliance"},{"key":"1203_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54545-4","volume":"14","author":"M-C Weber","year":"2024","unstructured":"Weber, M.-C. et al. Fractal analysis of extracellular matrix for observer-independent quantification of intestinal fibrosis in Crohn\u2019s disease. Sci. Rep. 14, 3988 (2024).","journal-title":"Sci. Rep."},{"key":"1203_CR192","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.actbio.2024.12.062","volume":"195","author":"MJ Emerson","year":"2025","unstructured":"Emerson, M. J. et al. Machine learning identifies remodeling patterns in human lung extracellular matrix. Acta Biomater. 195, 94\u2013103 (2025).","journal-title":"Acta Biomater."},{"key":"1203_CR193","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241307686","volume":"23","author":"X Li","year":"2024","unstructured":"Li, X. et al. Machine learning-based pathomics model to predict the prognosis in clear cell renal cell carcinoma. Technol. Cancer Res. Treat. 23, 15330338241307686 (2024).","journal-title":"Technol. Cancer Res. Treat."},{"key":"1203_CR194","doi-asserted-by":"publisher","first-page":"8662","DOI":"10.1128\/MCB.24.19.8662-8670.2004","volume":"24","author":"S Astrof","year":"2004","unstructured":"Astrof, S. et al. Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol. Cell. Biol. 24, 8662\u20138670 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"1203_CR195","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/iub.493","volume":"63","author":"ES White","year":"2011","unstructured":"White, E. S. & Muro, A. F. Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 63, 538\u2013546 (2011).","journal-title":"IUBMB Life"},{"key":"1203_CR196","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/j.1600-0625.2011.01314.x","volume":"20","author":"K Frey","year":"2011","unstructured":"Frey, K. et al. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp. Dermatol. 20, 685\u2013688 (2011).","journal-title":"Exp. Dermatol."},{"key":"1203_CR197","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/s41416-024-02882-6","volume":"131","author":"T Semba","year":"2024","unstructured":"Semba, T. & Ishimoto, T. Spatial analysis by current multiplexed imaging technologies for the molecular characterisation of cancer tissues. Br. J. Cancer 131, 1737\u20131747 (2024).","journal-title":"Br. J. Cancer"},{"key":"1203_CR198","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41568-023-00657-4","volume":"24","author":"N de Souza","year":"2024","unstructured":"de Souza, N., Zhao, S. & Bodenmiller, B. Multiplex protein imaging in tumour biology. Nat. Rev. Cancer 24, 171\u2013191 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR199","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00281-022-00974-0","volume":"45","author":"W Kuswanto","year":"2023","unstructured":"Kuswanto, W., Nolan, G. & Lu, G. Highly multiplexed spatial profiling with CODEX: bioinformatic analysis and application in human disease. Semin. Immunopathol. 45, 145\u2013157 (2023).","journal-title":"Semin. Immunopathol."},{"key":"1203_CR200","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","volume":"174","author":"Y Goltsev","year":"2018","unstructured":"Goltsev, Y. et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell 174, 968\u2013981.e15 (2018).","journal-title":"Cell"},{"key":"1203_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101248","volume":"4","author":"S Mascharak","year":"2023","unstructured":"Mascharak, S. et al. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Cell Rep. Med. 4, 101248 (2023).","journal-title":"Cell Rep. Med."},{"key":"1203_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104130","volume":"105","author":"G Andreev","year":"2025","unstructured":"Andreev, G. et al. Spatial correlation of the extracellular matrix to immune cell phenotypes in the tumor boundary of clear cell renal cell carcinoma revealed by cyclic immunohistochemistry. Lab. Invest. 105, 104130 (2025).","journal-title":"Lab. Invest."},{"key":"1203_CR203","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.matbio.2018.04.011","volume":"71\u201372","author":"S Rickelt","year":"2018","unstructured":"Rickelt, S. & Hynes, R. O. Antibodies and methods for immunohistochemistry of extracellular matrix proteins. Matrix Biol. 71\u201372, 10\u201327 (2018).","journal-title":"Matrix Biol."},{"key":"1203_CR204","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41592-023-01846-7","volume":"20","author":"EM Quardokus","year":"2023","unstructured":"Quardokus, E. M. et al. Organ mapping antibody panels: a community resource for standardized multiplexed tissue imaging. Nat. Methods 20, 1174\u20131178 (2023).","journal-title":"Nat. Methods"},{"key":"1203_CR205","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma, L. et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal. Transduct. Target. Ther. 9, 336 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1203_CR206","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.oraloncology.2011.09.002","volume":"48","author":"S Nurmenniemi","year":"2012","unstructured":"Nurmenniemi, S. et al. Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. Oral Oncol. 48, 136\u2013140 (2012).","journal-title":"Oral Oncol."},{"key":"1203_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56268-3","volume":"9","author":"N Willumsen","year":"2019","unstructured":"Willumsen, N. et al. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Sci. Rep. 9, 19761 (2019).","journal-title":"Sci. Rep."},{"key":"1203_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02701-z","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J. Transl. Med. 19, 39 (2021).","journal-title":"J. Transl. Med."},{"key":"1203_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10839-w","volume":"23","author":"G Ye","year":"2023","unstructured":"Ye, G. et al. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer. BMC Cancer 23, 412 (2023).","journal-title":"BMC Cancer"},{"key":"1203_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09691-3","volume":"7","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Serum fibronectin distinguishes the early stages of hepatocellular carcinoma. Sci. Rep. 7, 9449 (2017).","journal-title":"Sci. Rep."},{"key":"1203_CR211","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq3110","volume":"17","author":"JL Montoya Mira","year":"2025","unstructured":"Montoya Mira, J. L. et al. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Sci. Transl. Med. 17, eadq3110 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1203_CR212","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1586\/14789450.2016.1134327","volume":"13","author":"F Genovese","year":"2016","unstructured":"Genovese, F. & Karsdal, M. A. Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers. Expert Rev. Proteom. 13, 213\u2013225 (2016).","journal-title":"Expert Rev. Proteom."},{"key":"1203_CR213","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1074\/mcp.M114.044628","volume":"14","author":"B Soboti\u010d","year":"2015","unstructured":"Soboti\u010d, B. et al. Proteomic identification of cysteine cathepsin substrates shed from the surface of cancer cells. Mol. Cell. Proteom. 14, 2213\u20132228 (2015).","journal-title":"Mol. Cell. Proteom."},{"key":"1203_CR214","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1158\/0008-5472.CAN-23-3998","volume":"84","author":"G Xu","year":"2024","unstructured":"Xu, G. et al. Proteomic profiling of serum extracellular vesicles identifies diagnostic signatures and therapeutic targets in breast cancer. Cancer Res. 84, 3267\u20133285 (2024).","journal-title":"Cancer Res."},{"key":"1203_CR215","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s42003-019-0570-8","volume":"2","author":"S Rontogianni","year":"2019","unstructured":"Rontogianni, S. et al. Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping. Commun. Biol. 2, 325 (2019).","journal-title":"Commun. Biol."},{"key":"1203_CR216","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-021-00389-3","volume":"21","author":"GA Kwong","year":"2021","unstructured":"Kwong, G. A. et al. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat. Rev. Cancer 21, 655\u2013668 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114197","volume":"387","author":"A Giri","year":"2025","unstructured":"Giri, A. et al. Design of cathepsin-sensitive linkers for tumor-selective bioconjugate drug delivery. J. Controlled Rel. 387, 114197 (2025).","journal-title":"J. Controlled Rel."},{"key":"1203_CR218","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/path.6207","volume":"262","author":"J Thorlacius-Ussing","year":"2024","unstructured":"Thorlacius-Ussing, J. et al. The collagen landscape in cancer: profiling collagens in tumors and in circulation reveals novel markers of cancer-associated fibroblast subtypes. J. Pathol. 262, 22\u201336 (2024).","journal-title":"J. Pathol."},{"key":"1203_CR219","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0092-8674(83)90175-7","volume":"35","author":"JE Schwarzbauer","year":"1983","unstructured":"Schwarzbauer, J. E., Tamkun, J. W., Lemischka, I. R. & Hynes, R. O. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 35, 421\u2013431 (1983).","journal-title":"Cell"},{"key":"1203_CR220","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.1158\/0008-5472.CAN-07-1436","volume":"67","author":"J-N Rybak","year":"2007","unstructured":"Rybak, J.-N., Roesli, C., Kaspar, M., Villa, A. & Neri, D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 67, 10948\u201310957 (2007).","journal-title":"Cancer Res."},{"key":"1203_CR221","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.10662","volume":"102","author":"L Borsi","year":"2002","unstructured":"Borsi, L. et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75\u201385 (2002).","journal-title":"Int. J. Cancer"},{"key":"1203_CR222","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1007\/s00259-022-05870-1","volume":"49","author":"CD van der Heide","year":"2022","unstructured":"van der Heide, C. D. & Dalm, S. U. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur. J. Nucl. Med. Mol. Imaging 49, 4616\u20134641 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1203_CR223","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2147\/OTT.S480787","volume":"17","author":"E Prodi","year":"2024","unstructured":"Prodi, E., Neri, D. & De Luca, R. Tumor-homing antibody-cytokine fusions for cancer therapy. Onco Targets Ther. 17, 697\u2013715 (2024).","journal-title":"Onco Targets Ther."},{"key":"1203_CR224","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.drudis.2012.01.007","volume":"17","author":"N Pasche","year":"2012","unstructured":"Pasche, N. & Neri, D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov. Today 17, 583\u2013590 (2012).","journal-title":"Drug Discov. Today"},{"key":"1203_CR225","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1182\/bloodadvances.2021006909","volume":"6","author":"AF Berdel","year":"2022","unstructured":"Berdel, A. F. et al. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. Blood Adv. 6, 3684\u20133696 (2022).","journal-title":"Blood Adv."},{"key":"1203_CR226","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac244","volume":"1","author":"EA Lutz","year":"2022","unstructured":"Lutz, E. A. et al. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice. PNAS Nexus 1, pgac244 (2022).","journal-title":"PNAS Nexus"},{"key":"1203_CR227","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00262-019-02383-z","volume":"68","author":"B Weide","year":"2019","unstructured":"Weide, B. et al. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunol. Immunother. 68, 1547\u20131559 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"1203_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07055-1","volume":"20","author":"RIY Lieverse","year":"2020","unstructured":"Lieverse, R. I. Y. et al. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer 20, 557 (2020).","journal-title":"BMC Cancer"},{"key":"1203_CR229","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ijc.35145","volume":"156","author":"E Prodi","year":"2025","unstructured":"Prodi, E. et al. Tripokin: a multi-specific immunocytokine for cancer immunotherapy. Int. J. Cancer 156, 216\u2013228 (2025).","journal-title":"Int. J. Cancer"},{"key":"1203_CR230","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejca.2021.03.038","volume":"150","author":"C Schliemann","year":"2021","unstructured":"Schliemann, C. et al. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas. Eur. J. Cancer 150, 143\u2013154 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1203_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2026.102698","volume":"66","author":"T Virgilio","year":"2026","unstructured":"Virgilio, T. et al. Imaging-guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines. Transl. Oncol. 66, 102698 (2026).","journal-title":"Transl. Oncol."},{"key":"1203_CR232","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-015-1704-6","volume":"64","author":"R Danielli","year":"2015","unstructured":"Danielli, R. et al. Intralesional administration of L19-IL2\/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol. Immunother. 64, 999\u20131009 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"1203_CR233","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","volume":"21","author":"AT Hooper","year":"2022","unstructured":"Hooper, A. T. et al. Anti-extra domain B splice variant of fibronectin antibody-drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade. Mol. Cancer Ther. 21, 1462\u20131472 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"1203_CR234","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","volume":"4","author":"A Mansurov","year":"2020","unstructured":"Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. 4, 531\u2013543 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1203_CR235","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0401","volume":"9","author":"J Ishihara","year":"2017","unstructured":"Ishihara, J. et al. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci. Transl. Med. 9, eaan0401 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1203_CR236","doi-asserted-by":"publisher","first-page":"eaau3259","DOI":"10.1126\/scitranslmed.aau3259","volume":"11","author":"J Ishihara","year":"2019","unstructured":"Ishihara, J. et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci. Transl. Med. 11, eaau3259 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1203_CR237","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1586\/14737140.7.5.675","volume":"7","author":"DA Reardon","year":"2007","unstructured":"Reardon, D. A., Zalutsky, M. R. & Bigner, D. D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer. Ther. 7, 675\u2013687 (2007).","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"1203_CR238","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-05-2804","volume":"12","author":"SS Brack","year":"2006","unstructured":"Brack, S. S., Silacci, M., Birchler, M. & Neri, D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res. 12, 3200\u20133208 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR239","doi-asserted-by":"publisher","first-page":"S875","DOI":"10.1016\/j.annonc.2024.08.1453","volume":"35","author":"S Peters","year":"2024","unstructured":"Peters, S. et al. 1398TiP Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC). Ann. Oncol. 35, S875 (2024).","journal-title":"Ann. Oncol."},{"key":"1203_CR240","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1080\/14796694.2025.2596228","volume":"21","author":"M Reck","year":"2025","unstructured":"Reck, M. et al. Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score \u226550%: phase III study design. Future Oncol. 21, 3891\u20133901 (2025).","journal-title":"Future Oncol."},{"key":"1203_CR241","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3010","volume":"43","author":"K Sehgal","year":"2025","unstructured":"Sehgal, K. et al. Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)-directed antibody-drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001). J. Clin. Oncol. 43, 3010 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3010 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR242","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.apsb.2024.10.012","volume":"15","author":"H Sui","year":"2025","unstructured":"Sui, H. et al. Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin \u03b1v\u03b23-positive tumors: a first-in-human study. Acta Pharmaceutica Sin. B 15, 669\u2013680 (2025).","journal-title":"Acta Pharmaceutica Sin. B"},{"key":"1203_CR243","first-page":"P1300","volume":"64","author":"R Davis","year":"2023","unstructured":"Davis, R. et al. First-in-human study of the theranostic pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in pancreatic adenocarcinoma. J. Nucl. Med. 64, P1300 (2023).","journal-title":"J. Nucl. Med."},{"key":"1203_CR244","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/1878-0261.12520","volume":"13","author":"Y Tao","year":"2019","unstructured":"Tao, Y. et al. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma. Mol. Oncol. 13, 1855\u20131873 (2019).","journal-title":"Mol. Oncol."},{"key":"1203_CR245","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2026.119113","volume":"196","author":"DR Reddy","year":"2026","unstructured":"Reddy, D. R. et al. CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer. Biomed. Pharmacother. 196, 119113 (2026).","journal-title":"Biomed. Pharmacother."},{"key":"1203_CR246","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1158\/0008-5472.CAN-23-0510","volume":"83","author":"Y Bei","year":"2023","unstructured":"Bei, Y. et al. Targeting CD44 Variant 5 with an antibody\u2013drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma. Cancer Res. 83, 2405\u20132420 (2023).","journal-title":"Cancer Res."},{"key":"1203_CR247","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.mtbio.2022.100364","volume":"16","author":"M Li","year":"2022","unstructured":"Li, M., Zhang, Y., Zhang, Q. & Li, J. Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines. Mater. Today Bio 16, 100364 (2022).","journal-title":"Mater. Today Bio"},{"key":"1203_CR248","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc1821","volume":"6","author":"CM Overall","year":"2006","unstructured":"Overall, C. M. & Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227\u2013239 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"1203_CR249","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13277-013-0842-8","volume":"34","author":"E Hadler-Olsen","year":"2013","unstructured":"Hadler-Olsen, E., Winberg, J.-O. & Uhlin-Hansen, L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 34, 2041\u20132051 (2013).","journal-title":"Tumour Biol."},{"key":"1203_CR250","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcdb.2007.06.006","volume":"19","author":"B Fingleton","year":"2008","unstructured":"Fingleton, B. MMPs as therapeutic targets-still a viable option? Semin. Cell Dev. Biol. 19, 61\u201368 (2008).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1203_CR251","doi-asserted-by":"publisher","first-page":"jcs261898","DOI":"10.1242\/jcs.261898","volume":"137","author":"S Hey","year":"2024","unstructured":"Hey, S. & Linder, S. Matrix metalloproteinases at a glance. J. Cell Sci. 137, jcs261898 (2024).","journal-title":"J. Cell Sci."},{"key":"1203_CR252","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3390\/cancers14071847","volume":"14","author":"K Augoff","year":"2022","unstructured":"Augoff, K., Hryniewicz-Jankowska, A., Tabola, R. & Stach, K. MMP9: a tough target for targeted therapy for cancer. Cancers 14, 1847 (2022).","journal-title":"Cancers"},{"key":"1203_CR253","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.bbamcr.2017.06.009","volume":"1864","author":"M Levin","year":"2017","unstructured":"Levin, M., Udi, Y., Solomonov, I. & Sagi, I. Next generation matrix metalloproteinase inhibitors \u2014 novel strategies bring new prospects. Biochim. Biophys. Acta Mol. Cell Res. 1864, 1927\u20131939 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1203_CR254","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.tibs.2025.08.002","volume":"50","author":"N Rotenberg","year":"2025","unstructured":"Rotenberg, N., Bentolila, N. Y. & Shifman, J. M. Engineered protein inhibitors for precise targeting of matrix metalloproteinases. Trends Biochem. Sci. 50, 919\u2013930 (2025).","journal-title":"Trends Biochem. Sci."},{"key":"1203_CR255","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29335","volume":"96","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. TS-2021, a third-generation oncolytic adenovirus that carried Ki67 promoter, TGF-\u03b22 5\u2019UTR, and IL-15 against experimental glioblastoma. J. Med. Virol. 96, e29335 (2024).","journal-title":"J. Med. Virol."},{"key":"1203_CR256","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1042\/EBC20180050","volume":"63","author":"SD Vallet","year":"2019","unstructured":"Vallet, S. D. & Ricard-Blum, S. Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. Essays Biochem. 63, 349\u2013364 (2019).","journal-title":"Essays Biochem."},{"key":"1203_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2025.151527","volume":"105","author":"DL Boaru","year":"2026","unstructured":"Boaru, D. L. et al. The role of the LOX family in cancer. Eur. J. Cell Biol. 105, 151527 (2026).","journal-title":"Eur. J. Cell Biol."},{"key":"1203_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107633","volume":"215","author":"M Ye","year":"2020","unstructured":"Ye, M. et al. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy. Pharmacol. Ther. 215, 107633 (2020).","journal-title":"Pharmacol. Ther."},{"key":"1203_CR259","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s43018-023-00614-y","volume":"4","author":"JL Chitty","year":"2023","unstructured":"Chitty, J. L. et al. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nat. Cancer 4, 1326\u20131344 (2023).","journal-title":"Nat. Cancer"},{"key":"1203_CR260","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5009\/gnl17569","volume":"13","author":"J Choi","year":"2019","unstructured":"Choi, J. et al. Increased expression of the matrix-modifying enzyme lysyl oxidase-like 2 in aggressive hepatocellular carcinoma with poor prognosis. Gut Liver 13, 83\u201392 (2019).","journal-title":"Gut Liver"},{"key":"1203_CR261","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/crj.12584","volume":"12","author":"P Zhan","year":"2018","unstructured":"Zhan, P., Lv, X.-J., Ji, Y.-N., Xie, H. & Yu, L.-K. Increased lysyl oxidase-like 2 associates with a poor prognosis in non-small cell lung cancer. Clin. Respir. J. 12, 712\u2013720 (2018).","journal-title":"Clin. Respir. J."},{"key":"1203_CR262","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1042\/BST20190098","volume":"47","author":"JL Chitty","year":"2019","unstructured":"Chitty, J. L., Setargew, Y. F. I. & Cox, T. R. Targeting the lysyl oxidases in tumour desmoplasia. Biochem. Soc. Trans. 47, 1661\u20131678 (2019).","journal-title":"Biochem. Soc. Trans."},{"key":"1203_CR263","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.15252\/emmm.201404827","volume":"7","author":"BW Miller","year":"2015","unstructured":"Miller, B. W. et al. Targeting the LOX\/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol. Med. 7, 1063\u20131076 (2015).","journal-title":"EMBO Mol. Med."},{"key":"1203_CR264","doi-asserted-by":"publisher","first-page":"9198","DOI":"10.7150\/thno.62455","volume":"11","author":"G Zhu","year":"2021","unstructured":"Zhu, G. et al. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer. Theranostics 11, 9198\u20139216 (2021).","journal-title":"Theranostics"},{"key":"1203_CR265","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.3324\/haematol.2024.287231","volume":"110","author":"P Vachhani","year":"2025","unstructured":"Vachhani, P. et al. A phase I\/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis. Haematologica 110, 2376\u20132387 (2025).","journal-title":"Haematologica"},{"key":"1203_CR266","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/2159-8290.CD-11-0136","volume":"1","author":"CJ Whatcott","year":"2011","unstructured":"Whatcott, C. J., Han, H., Posner, R. G., Hostetter, G. & Von Hoff, M. D. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 1, 291\u2013296 (2011).","journal-title":"Cancer Discov."},{"key":"1203_CR267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2019.02.002","volume":"78\u201379","author":"S Garantziotis","year":"2019","unstructured":"Garantziotis, S. & Savani, R. C. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 78\u201379, 1\u201310 (2019).","journal-title":"Matrix Biol."},{"key":"1203_CR268","doi-asserted-by":"publisher","first-page":"C1187","DOI":"10.1152\/ajpcell.00063.2022","volume":"322","author":"R Wieboldt","year":"2022","unstructured":"Wieboldt, R. & L\u00e4ubli, H. Glycosaminoglycans in cancer therapy. Am. J. Physiol. Cell Physiol. 322, C1187\u2013C1200 (2022).","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"1203_CR269","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.2012.569","volume":"108","author":"PP Provenzano","year":"2013","unstructured":"Provenzano, P. P. & Hingorani, S. R. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br. J. Cancer 108, 1\u20138 (2013).","journal-title":"Br. J. Cancer"},{"key":"1203_CR270","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62, 112\u2013120 (2013).","journal-title":"Gut"},{"key":"1203_CR271","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62645","volume":"10","author":"PK Kim","year":"2021","unstructured":"Kim, P. K. et al. Hyaluronic acid fuels pancreatic cancer cell growth. eLife 10, e62645 (2021).","journal-title":"eLife"},{"key":"1203_CR272","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418\u2013429 (2012).","journal-title":"Cancer Cell"},{"key":"1203_CR273","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","volume":"22","author":"SR Hingorani","year":"2016","unstructured":"Hingorani, S. R. et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin. Cancer Res. 22, 2848\u20132854 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR274","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/JCO.18.01295","volume":"37","author":"RK Ramanathan","year":"2019","unstructured":"Ramanathan, R. K. et al. Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J. Clin. Oncol. 37, 1062\u20131069 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR275","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185\u20133194 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR276","doi-asserted-by":"publisher","first-page":"107958","DOI":"10.1016\/j.phrs.2025.107958","volume":"221","author":"W Cai","year":"2025","unstructured":"Cai, W., Chen, Y., Dai, S., Zhao, J. & Chen, L. Hyaluronic acid and its role in pancreatic cancer: mechanisms of tumor progression, drug resistance, and therapeutic targeting. Pharmacol. Res. 221, 107958 (2025).","journal-title":"Pharmacol. Res."},{"key":"1203_CR277","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1158\/1078-0432.CCR-26-0601","volume":"32","author":"M Jove","year":"2026","unstructured":"Jove, M. et al. Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy. Clin. Cancer Res. 32, 3786\u20133798 https:\/\/doi.org\/10.1158\/1078-0432.CCR-26-0601 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR278","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003254","volume":"9","author":"M Bazan-Peregrino","year":"2021","unstructured":"Bazan-Peregrino, M. et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J. Immunother. Cancer 9, e003254 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1203_CR279","doi-asserted-by":"publisher","first-page":"S1146","DOI":"10.1016\/j.annonc.2025.08.2833","volume":"36","author":"R Garcia-Carbonero","year":"2025","unstructured":"Garcia-Carbonero, R. et al. 2216MO VIRAGE trial: randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with\/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC). Ann. Oncol. 36, S1146\u2013S1147 (2025).","journal-title":"Ann. Oncol."},{"key":"1203_CR280","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003255","volume":"10","author":"R Garcia-Carbonero","year":"2022","unstructured":"Garcia-Carbonero, R. et al. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J. Immunother. Cancer 10, e003255 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1203_CR281","doi-asserted-by":"publisher","first-page":"107245","DOI":"10.1016\/j.phrs.2024.107245","volume":"205","author":"I Fuster-Mart\u00ednez","year":"2024","unstructured":"Fuster-Mart\u00ednez, I. & Calatayud, S. The current landscape of antifibrotic therapy across different organs: a systematic approach. Pharmacol. Res. 205, 107245 (2024).","journal-title":"Pharmacol. Res."},{"key":"1203_CR282","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","volume":"57","author":"L Kn\u00fcppel","year":"2017","unstructured":"Kn\u00fcppel, L. et al. A novel antifibrotic mechanism of nintedanib and pirfenidone. inhibition of collagen fibril assembly. Am. J. Respir. Cell Mol. Biol. 57, 77\u201390 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1203_CR283","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","volume":"62","author":"SM Ruwanpura","year":"2020","unstructured":"Ruwanpura, S. M., Thomas, B. J. & Bardin, P. G. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am. J. Respir. Cell Mol. Biol. 62, 413\u2013422 (2020).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1203_CR284","volume":"43","author":"SJ Khan","year":"2025","unstructured":"Khan, S. J. et al. Role of pirfenidone in the primary prophylaxis of lung cancer in idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis. J. Clin. Oncol. 43, e22514 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR285","doi-asserted-by":"publisher","first-page":"2401484","DOI":"10.1183\/13993003.01484-2024","volume":"65","author":"H-Y Yoon","year":"2025","unstructured":"Yoon, H.-Y., Kim, H., Bae, Y. & Song, J. W. Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study. Eur. Respir. J. 65, 2401484 (2025).","journal-title":"Eur. Respir. J."},{"key":"1203_CR286","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","volume":"103","author":"DS Lim","year":"2001","unstructured":"Lim, D. S. et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103, 789\u2013791 (2001).","journal-title":"Circulation"},{"key":"1203_CR287","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan, V. P. et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516 (2013).","journal-title":"Nat. Commun."},{"key":"1203_CR288","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1073\/pnas.1018892108","volume":"108","author":"B Diop-Frimpong","year":"2011","unstructured":"Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y. & Jain, R. K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl Acad. Sci. USA 108, 2909\u20132914 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1203_CR289","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41416-024-02863-9","volume":"131","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer. Br. J. Cancer 131, 1683\u20131693 (2024).","journal-title":"Br. J. Cancer"},{"key":"1203_CR290","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.xcrm.2025.102395","volume":"6","author":"V Boeker","year":"2025","unstructured":"Boeker, V. & Kalluri, R. Insights into the relevance of targeting fibroblasts to control cancer. Cell Rep. Med. 6, 102395 (2025).","journal-title":"Cell Rep. Med."},{"key":"1203_CR291","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1100\u20131108 (2014).","journal-title":"Lancet Oncol."},{"key":"1203_CR292","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cncr.24821","volume":"116","author":"P Hersey","year":"2010","unstructured":"Hersey, P. et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin \u03b1v\u03b23, \u00b1 dacarbazine in patients with stage IV metastatic melanoma. Cancer 116, 1526\u20131534 (2010).","journal-title":"Cancer"},{"key":"1203_CR293","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/1078-0432.CCR-15-2512","volume":"22","author":"M Hussain","year":"2016","unstructured":"Hussain, M. et al. Differential effect on bone lesions of targeting integrins: randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 22, 3192\u20133200 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR294","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/annonc\/mdu474","volume":"26","author":"E \u00c9lez","year":"2015","unstructured":"\u00c9lez, E. et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I\/II POSEIDON trial. Ann. Oncol. 26, 132\u2013140 (2015).","journal-title":"Ann. Oncol."},{"key":"1203_CR295","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006720","volume":"11","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer. J. Immunother. Cancer 11, e006720 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1203_CR296","doi-asserted-by":"publisher","first-page":"jcs261723","DOI":"10.1242\/jcs.261723","volume":"137","author":"DD Schlaepfer","year":"2024","unstructured":"Schlaepfer, D. D., Ojalill, M. & Stupack, D. G. Focal adhesion kinase signaling \u2014 tumor vulnerabilities and clinical opportunities. J. Cell Sci. 137, jcs261723 (2024).","journal-title":"J. Cell Sci."},{"key":"1203_CR297","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell, D. A. et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND \u2014 a double-blind, randomized, phase II study. J. Clin. Oncol. 37, 790\u2013798 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR298","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO-25-00112","volume":"43","author":"SN Banerjee","year":"2025","unstructured":"Banerjee, S. N. et al. Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201. J. Clin. Oncol. 43, 2782\u20132792 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR299","doi-asserted-by":"publisher","first-page":"8605","DOI":"10.1200\/JCO.2024.42.16_suppl.8605","volume":"42","author":"Z Song","year":"2024","unstructured":"Song, Z. et al. Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: results from a phase Ib\/II study. J. Clin. Oncol. 42, 8605 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR300","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1038\/s41591-025-03763-y","volume":"31","author":"S Banerjee","year":"2025","unstructured":"Banerjee, S. et al. Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial. Nat. Med. 31, 3074\u20133080 (2025).","journal-title":"Nat. Med."},{"key":"1203_CR301","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2026.44.2_suppl.735","volume":"44","author":"N Pavlakis","year":"2026","unstructured":"Pavlakis, N. et al. Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer (ACCENT trial): phase 2a results. J. Clin. Oncol. 44, 735\u2013735 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1203_CR302","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00262-017-2003-1","volume":"66","author":"H Jiang","year":"2017","unstructured":"Jiang, H., Hegde, S. & DeNardo, D. G. Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol. Immunother. 66, 1037\u20131048 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"1203_CR303","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41577-025-01248-0","volume":"26","author":"L Sorokin","year":"2026","unstructured":"Sorokin, L. Biochemical signals from the extracellular matrix in inflammation and tumour immunology. Nat. Rev. Immunol. 26, 350\u2013366 https:\/\/doi.org\/10.1038\/s41577-025-01248-0 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"1203_CR304","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899\u2013910 (2012).","journal-title":"J. Clin. Invest."},{"key":"1203_CR305","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013270","volume":"13","author":"D Murdamoothoo","year":"2021","unstructured":"Murdamoothoo, D. et al. Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression. EMBO Mol. Med. 13, e13270 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1203_CR306","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk3327","volume":"8","author":"MD Bunting","year":"2022","unstructured":"Bunting, M. D. et al. Extracellular matrix proteins regulate NK cell function in peripheral tissues. Sci. Adv. 8, eabk3327 (2022).","journal-title":"Sci. Adv."},{"key":"1203_CR307","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/EDBK_237987","volume":"39","author":"M Datta","year":"2019","unstructured":"Datta, M., Coussens, L. M., Nishikawa, H., Hodi, F. S. & Jain, R. K. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am. Soc. Clin. Oncol. Educ. Book. 39, 165\u2013174 (2019).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"1203_CR308","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1158\/0008-5472.CAN-18-3060","volume":"79","author":"R Clift","year":"2019","unstructured":"Clift, R., Souratha, J., Garrovillo, S. A., Zimmerman, S. & Blouw, B. Remodeling the tumor microenvironment sensitizes breast tumors to anti-programmed death-ligand 1 immunotherapy. Cancer Res. 79, 4149\u20134159 (2019).","journal-title":"Cancer Res."},{"key":"1203_CR309","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58688","volume":"10","author":"A Nicolas-Boluda","year":"2021","unstructured":"Nicolas-Boluda, A. et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife 10, e58688 (2021).","journal-title":"eLife"},{"key":"1203_CR310","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-19-0187","volume":"25","author":"T-L Yeung","year":"2019","unstructured":"Yeung, T.-L. et al. Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer. Clin. Cancer Res. 25, 6417\u20136428 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1203_CR311","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524\u2013529 (2015).","journal-title":"Nat. Med."},{"key":"1203_CR312","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1053\/j.gastro.2022.06.027","volume":"163","author":"AB Blair","year":"2022","unstructured":"Blair, A. B. et al. Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-programmed cell death protein 1 therapy. Gastroenterology 163, 1267\u20131280.e7 (2022).","journal-title":"Gastroenterology"},{"key":"1203_CR313","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404485121","volume":"121","author":"C Li","year":"2024","unstructured":"Li, C. et al. Targeting the MAtrix REgulating MOtif abolishes several hallmarks of cancer, triggering antitumor immunity. Proc. Natl Acad. Sci. USA 121, e2404485121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1203_CR314","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","volume":"599","author":"X Sun","year":"2021","unstructured":"Sun, X. et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature 599, 673\u2013678 (2021).","journal-title":"Nature"},{"key":"1203_CR315","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63415-0","volume":"16","author":"B Hu","year":"2025","unstructured":"Hu, B. et al. Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA. Nat. Commun. 16, 8120 (2025).","journal-title":"Nat. Commun."},{"key":"1203_CR316","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","volume":"8","author":"DA Thomas","year":"2005","unstructured":"Thomas, D. A. & Massagu\u00e9, J. TGF-\u03b2 directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369\u2013380 (2005).","journal-title":"Cancer Cell"},{"key":"1203_CR317","doi-asserted-by":"publisher","first-page":"16618","DOI":"10.1073\/pnas.1117610109","volume":"109","author":"J Liu","year":"2012","unstructured":"Liu, J. et al. TGF-\u03b2 blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc. Natl Acad. Sci. USA 109, 16618\u201316623 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1203_CR318","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"1203_CR319","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello, D. V. F. et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538\u2013543 (2018).","journal-title":"Nature"},{"key":"1203_CR320","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications. Int. J. Biol. Sci. 19, 3341\u20133359 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"1203_CR321","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.clinre.2015.09.005","volume":"40","author":"J-Y Park","year":"2016","unstructured":"Park, J.-Y. et al. Polarized CD163+ tumor-associated macrophages are associated with increased angiogenesis and CXCL12 expression in gastric cancer. Clin. Res. Hepatol. Gastroenterol. 40, 357\u2013365 (2016).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"1203_CR322","first-page":"1099","volume":"18","author":"B Zhang","year":"2019","unstructured":"Zhang, B. et al. CXCL12 is associated with FoxP3+ tumor-infiltrating lymphocytes and affects the survival of patients with oral squamous cell carcinoma. Oncol. Lett. 18, 1099\u20131106 (2019).","journal-title":"Oncol. Lett."},{"key":"1203_CR323","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P. & Kalinski, P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71, 7463\u20137470 (2011).","journal-title":"Cancer Res."},{"key":"1203_CR324","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1203_CR325","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1096\/fj.201802067RR","volume":"33","author":"Y Zeng","year":"2019","unstructured":"Zeng, Y. et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 33, 6596\u20136608 (2019).","journal-title":"FASEB J."},{"key":"1203_CR326","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1073\/pnas.1815515116","volume":"116","author":"IX Chen","year":"2019","unstructured":"Chen, I. X. et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc. Natl Acad. Sci. USA 116, 4558\u20134566 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1203_CR327","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/1873-3468.14852","volume":"598","author":"JK Macdonald","year":"2024","unstructured":"Macdonald, J. K., Mehta, A. S., Drake, R. R. & Angel, P. M. Molecular analysis of the extracellular microenvironment: from form to function. FEBS Lett. 598, 602\u2013620 (2024).","journal-title":"FEBS Lett."},{"key":"1203_CR328","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.sbi.2019.10.006","volume":"60","author":"N de Souza","year":"2020","unstructured":"de Souza, N. & Picotti, P. Mass spectrometry analysis of the structural proteome. Curr. Opin. Struct. Biol. 60, 57\u201365 (2020).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"1203_CR329","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10585-019-09972-3","volume":"36","author":"A Zijlstra","year":"2019","unstructured":"Zijlstra, A. et al. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin. Exp. Metastasis 36, 305\u2013309 (2019).","journal-title":"Clin. Exp. Metastasis"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01203-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:02:35Z","timestamp":1790002955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01203-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":329,"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01203-5","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"28 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.N. has received research funding from Boehringer\u2013Ingelheim for work not related to the content of this manuscript. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}